2026-04-17T03:14:24Zhttps://recercat.cat/oai/request

oai:recercat.cat:2445/2281272026-04-08T14:08:16Zcom_2072_1057col_2072_478916col_2072_478917

urn:hdl:2445/228127 Personalized prevention of neurodegenerative diseases: scoping review and evidence gap map Barahona López, Cristina Plans Beriso, Elena Diez Echave, Paul Hernández, Orlando Fernández de Larrea, Nerea Craciun, Oana García Ovejero, Ester Petrova, Dafina Fernández Martínez, Nicolás Francisco Arruabarrena Blanco, Estíbaliz Babb de Villiers, Chantal Turner, Heather Cierco Jimenez, Ramon Erady, Chaitanya Wilson, Hayley Fernández Navarro, Pablo García García-Esquinas, Esther Kuhn, Isla Sánchez Juan, Pascual Rodríguez-Artalejo, Fernando Sánchez Pérez, María José Moreno Aguado, Víctor Blackburn, Laura Pollán, Marina Kroese, Mark Pérez Gómez, Beatriz Malalties neurodegeneratives Salut pública Neurodegenerative Diseases Public health Neurodegenerative diseases represent a major public health challenge due to their high prevalence and poor prognosis. Identifying biomarkers to stratify individuals by their risk of developing these diseases may help to define new personalized prevention interventions. The objective of this study was to conduct a scoping review of biomarkers for primary and secondary personalized prevention of neurodegenerative diseases. The search targeted biomarkers in adults or high-risk subpopulations in clinical or public health settings for Alzheimer's disease, vascular dementia, Lewy body disease, frontotemporal dementia, Parkinson's disease, multiple sclerosis, and amyotrophic lateral sclerosis. Ultimately, 286 papers were included in the review and the interactive gap map. There is a strong focus on Alzheimer's disease, and most papers included -omics-based biomarkers and/or used artificial intelligence. Genetics/genomics are at the forefront of current scientific research, although there is a notable gap in studying gene-environment interactions, and studies in clinical settings are still scarce.Highlights Research indicates a strong focus on Alzheimers disease and limited research in other diseases. Genetics and genomics are at the forefront of current scientific research. We found biomarkers for predicting progression in mild cognitive decline. There is a notable gap in studying gene-environment interactions. Studies investigating biomarkers in a clinical context are still scarce. 2026-03-16T12:05:27Z 2026-03-16T12:05:27Z 2025-12-01 2026-02-05T10:32:59Z info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion Reproducció del document publicat a: https://doi.org/10.1002/alz.70980 Alzheimer s & Dementia, 2025, vol. 21, num. 12 https://doi.org/10.1002/alz.70980 cc-by-nc (c) Barahona López, Cristina et al., 2025 http://creativecommons.org/licenses/by-nc/4.0/ info:eu-repo/semantics/openAccess Wiley Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))